Literature DB >> 9561344

Recognition and treatment of idiopathic pulmonary fibrosis.

L P Nicod1.   

Abstract

The diagnosis of idiopathic pulmonary fibrosis can be made only after exclusion of other entities such as neoplasm, toxic treatments, collagen vascular diseases, occupational exposure or granulomatous diseases, such as sarcoidosis. The repercussions on gas exchanges are the most reliable indications of the severity of the disease, the measure of lung volume or chest x-rays alone often being misleading. Biopsies obtained during transbronchial procedures by thoracoscopies or thoracotomy are of great help, but mainly to rule out other diseases. In many cases, only a high resolution computerised tomography (CT) scan and bronchoalveolar lavage are performed to rule out infection or tumour and to assess the inflammatory state of the disease. Due to the fact that barely a quarter of patients respond to corticosteroids alone, cytostatics (in particular azathioprine) are often prescribed simultaneously with low dose corticosteroids, either initially or after an unsuccessful trial of corticosteroids. Cyclosporin has been useful for only a limited number of patients. Colchicine has been shown useful in an open trial but its role still needs to be assessed. Anticytokine therapy and the role of substances such as relaxin are still at the experimental stage. Lung transplantation is now a therapeutic option for selected patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9561344     DOI: 10.2165/00003495-199855040-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients.

Authors:  M Taniyama; S Ohbayashi; M Narita; R Nakazawa; S Hasegawa; N Azuma; S Teraoka; K Ota; S Yamauchi; S B Margolin
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

2.  Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.

Authors:  A M Cantin; R C Hubbard; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1989-02

3.  A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.

Authors:  L C Watters; T E King; M I Schwarz; J A Waldron; R E Stanford; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1986-01

Review 4.  Approaches to the treatment of pulmonary fibrosis.

Authors:  G W Hunninghake; A R Kalica
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

5.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

6.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

7.  Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.

Authors:  E N Unemori; L B Pickford; A L Salles; C E Piercy; B H Grove; M E Erikson; E P Amento
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 8.  High resolution lung computed tomography. Normal anatomic and pathologic findings.

Authors:  W R Webb
Journal:  Radiol Clin North Am       Date:  1991-09       Impact factor: 2.303

9.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Authors:  T J Broekelmann; A H Limper; T V Colby; J A McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

10.  GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome.

Authors:  J Villard; F Dayer-Pastore; J Hamacher; J D Aubert; S Schlegel-Haueter; L P Nicod
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.